Pay in 4 interest-free payments of $5.35 Learn more
Ships within 48 hours · Estimated delivery Sep 11 - Sep 16
[56] [57] Economic evaluations of GLP-1 receptor agonists for non-diabetic obesity have reported incremental cost-effectiveness ratios well above common willingness-to-pay thresholds, including estimates in the approximate range of $237,000-$483,000 per quality-adjusted life-year in some U.S.-based models
Such differences are increasingly being viewed as important for biological understanding, with the potential for biological differentiation between small molecule and peptide agonists, and perhaps greater efficacy
[8] Liu JR, et al
You also may have a higher risk of miscarriage
Ozempic: 0.251 mg weekly
Each weekly injection delivers a controlled release of the drug over roughly seven days
US$ 24.81
US$ 28.10
US$ 22.33
US$ 23.18
